Embecta Corp
$ 12.39
6.63%
06 Jan - close price
- Market Cap 688,043,000 USD
- Current Price $ 12.39
- High / Low $ 12.44 / 11.57
- Stock P/E 7.17
- Book Value -11.12
- EPS 1.62
- Next Earning Report 2026-02-05
- Dividend Per Share $0.60
- Dividend Yield 5.15 %
- Next Dividend Date -
- ROA 0.17 %
- ROE N/A %
- 52 Week High 19.66
- 52 Week Low 8.99
About
None
Analyst Target Price
$16.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-25 | 2025-08-08 | 2025-05-07 | 2025-02-07 | 2024-11-19 | 2024-08-09 | 2024-05-09 | 2024-02-09 | 2023-11-21 | 2023-08-08 | 2023-05-12 | 2023-02-14 |
| Reported EPS | 0.5 | 0.78 | 0.7 | 0.65 | 0.45 | 0.74 | 0.67 | 0.61 | 0.59 | 0.26 | 0.24 | 0.96 |
| Estimated EPS | 0.46 | 0.77 | 0.5875 | 0.4425 | 0.36 | 0.46 | 0.4 | 0.46 | 0.4 | 0.46 | 0.49 | 0.52 |
| Surprise | 0.04 | 0.01 | 0.1125 | 0.2075 | 0.09 | 0.28 | 0.27 | 0.15 | 0.19 | -0.2 | -0.25 | 0.44 |
| Surprise Percentage | 8.6957% | 1.2987% | 19.1489% | 46.8927% | 25% | 60.8696% | 67.5% | 32.6087% | 47.5% | -43.4783% | -51.0204% | 84.6154% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.67 |
| Currency | USD |
Previous Dividend Records
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-18 | 2025-09-15 | 2025-06-13 | 2025-03-14 | 2024-12-18 | 2024-09-13 | 2024-06-14 | 2024-03-15 | 2023-12-15 | 2023-09-13 |
| Amount | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EMBC
2026-01-06 11:24:00
This article analyzes Embecta Corp. (NASDAQ: EMBC) with a focus on its price dynamics and positioning strategies. It highlights a near-term weak sentiment that could lead to a resumption of long-term weakness and identifies a high risk-reward short setup. The analysis provides specific trading strategies and multi-timeframe signal analysis generated by AI models for different risk profiles.
2025-12-27 09:09:54
Exchange Traded Concepts LLC significantly increased its stake in Embecta Corp. (NASDAQ:EMBC) by 519.2% in the third quarter, adding 104,334 shares to now hold 124,429 shares valued at approximately $1.76 million. Other institutional investors like American Century Companies Inc., River Road Asset Management LLC, and Yacktman Asset Management LP also adjusted their holdings. Embecta has a market capitalization of $711.11 million, a PE ratio of 7.37, and offers a 5.0% dividend yield, with analysts forecasting 2.85 earnings per share for the current year.
2025-12-26 10:00:00
This article provides a detailed analysis of Embecta Corp. (EMBC) using AI models to suggest precision trading strategies. It highlights a stable neutral reading in shorter horizons, testing of support levels, and a significant risk-reward setup targeting a 25.1% gain. The piece outlines three distinct trading strategies tailored for different risk profiles.
2025-12-22 22:08:34
Embecta (EMBC) reported stronger-than-expected Q4 earnings, driven by improved margins despite a slight decline in revenue. The company also provided a positive outlook for fiscal 2024, forecasting adjusted EBITDA growth between 7.5% and 9.5%.
2025-12-19 02:10:06
Embecta Corp. announced its management will present at the J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The presentation will be webcast live on the company's investor relations website. Embecta is a global medical supplies company focused on insulin delivery and other innovative healthcare solutions.
2025-12-18 22:10:08
Embecta Corp. (embecta) announced that its management will present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. PT. Audio webcasts of the presentation will be available on the company's investor relations website. Embecta is evolving its insulin delivery legacy into a broad-based medical supplies company.
